MedTrace Logo

Dose Range Study of CD5789 in Acne Vulgaris

NCT01616654 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 304

Last updated 2021-09-20

Study results available
· View outcomes & findings →

Summary

To assess the efficacy and safety of different concentrations of CD5789 cream in participants with acne vulgaris for the purpose of dose identification.

Conditions

  • Acne Vulgaris

Interventions

DRUG

CD5789 25 µg/g cream

CD5789 25 µg/g cream applied once daily

DRUG

CD5789 50 µg/g cream

CD5789 50 µg/g cream applied once daily

DRUG

CD5789 100 µg/g cream

CD5789 100 µg/g cream applied once daily

DRUG

Tazarotene 0.1% gel

Tazarotene 0.1% gel applied once daily

DRUG

Vehicle cream

Vehicle cream applied once daily

Sponsors & Collaborators

  • Galderma R&D

    lead INDUSTRY

Principal Investigators

  • Michael Graeber, M.D. · Galderma R&D, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-20
Primary Completion
2013-07-24
Completion
2014-06-12

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01616654 on ClinicalTrials.gov